Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 3/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 8/20 | 0.34 |
| ▸ | CES1 | P23141 | 5/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14831463 | 0.90 | LMNA (0.62) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL23015199 | 0.90 | LMNA (0.62) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL16845302 | 0.90 | LMNA (0.62) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL14830449 | 0.90 | LMNA (0.62) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL4023703 | 0.86 | SMN1; SMN2 (0.37) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL11685471 | 0.86 | TSHR (0.40) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL20128921 | 0.81 | — | — | |
| SCHEMBL6085851 | 0.81 | — | — | |
| SCHEMBL11867732 | 0.80 | TSHR (0.35) | LMNAHSD17B10MEN1KMT2ATSHR | |
| SCHEMBL21061177 | 0.80 | LMNA (0.48) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702396-B2 | Hydrophobic compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702396-B2 | Hydrophobic compounds for optically active devices | UACA, CRYZ, TRPA1 | SMN1; SMN2 4872/4885LMNA 2186/4885ALDH1A1 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.